All News

The panel recommended that baseline PSA testing be done in Black men between the ages of 40 to 45.

“The more informed the patients are, the more likely they are to participate in decision making…Patient engagement in decisions reduces decisional regret and fosters patient satisfaction with treatment outcomes,” the researchers wrote.

"It adds to the evidence base that is building that shows that improving your fitness levels is a positive thing to do to reduce your risk of developing prostate cancer," says Kate A. Bolam Enarsson, PhD.

The clearance will initiate the phase 2 CELLVX-230 trial, which will assess the therapy in patients with prostate cancer with a high risk of recurrence following prostatectomy.

Clinical benefit with olaparib plus abiraterone was observed in patients with BRCA2, ATM, and CDK12 mutations, which were the most prevalent single-gene HRR mutations across all patients treated.

"Certainly germline and somatic is recommended for all mCRPC patients to detect HR gene mutations, and consider options for PARP inhibitors,” says Neal Shore, MD, FACS.

“HRR testing in patients before or at the time of mCRPC [diagnosis] would allow for olaparib therapy earlier in the disease course and potentially greater clinical benefit," wrote Daniel J. George, MD, and colleagues.

Drug-related hematological treatment-emergent adverse events were proportionately similar between the EBRT cohort and the those who did not receive EBRT to the bone.

Data showed that treatment with radical prostatectomy was associated with worse urinary incontinence but not worse sexual function compared with other treatment options, regardless of cancer risk.

Patients were less likely to choose active surveillance when their decision was influenced by their treatment goals of achieving “cure” or to “live longer,” or when they perceived their diagnosis of low-risk prostate cancer to be more serious.

"In deciding whom to discharge within hours of a less invasive but major surgery, we must ask ourselves which master we are serving: the insurer, the administrator, or our own ego," writes Badar M. Mian, MD.

Neeraj Agarwal, MD, discusses an analysis from the phase 3 TITAN trial that explored the correlation between PSA response and survival among patients with metastatic castration-sensitive prostate cancer receiving apalutamide.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

The phase 1/2 study is scheduled to commence in the first half of 2024.

The combination is approved for the treatment of patients with metastatic castration-resistant prostate cancer, regardless of mutation status.

The study is enrolling patients with relapsed/refractory metastatic castration-resistant prostate cancer who have received at least 1 next-generation androgen receptor pathway inhibitor.

The phase 1/2a CYPIDES trial assessed the safety and preliminary efficacy of ODM-208 in heavily pretreated patients with metastatic castration-resistant prostate cancer.

The payment rate for the prostate cancer test went into effect on January 1, 2024.

The open-label CaRe PC trial plans to enroll up to 30 adult patients with mCRPC, who will be treated across 3 dose levels of INKmune.

Over a decade of data document a continued increase in the use of hypofractionation in patients with localized prostate cancer.

Over the past year, the FDA approved a multitude of new treatments and devices for use in urology practice.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

"This study, using a novel technology to manage hot flashes, truly moves the field forward in improving the quality of life for men with prostate cancer,” says Alicia K. Morgans, MD, MPH.

Investigators analyzed data from over 1300 patients undergoing treatment for prostate cancer at 5 hospitals.

A response by the FDA is expected by February 2024.

Eric J. Small, MD, is an international leader in prostate cancer research and has published more than 430 peer-reviewed articles.

In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.

Dr. Shawn Zimberg and Dr. Dean Laganosky discuss the BioProtect Balloon Transplant System, a rectal spacer for use in prostate cancer radiation.

“The study highlights the importance of considering how altering cell metabolism could impact prostate cancer and its response to treatment," says Jenna Giafaglione.

“This next-generation rectal spacing option is the first of its kind...and has the potential to provide an enhanced degree of protection from the genitourinary and rectal effects of prostate cancer radiation therapy,” said Dr. Laganosky.